Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Region Skane
Sponsor:
Information provided by (Responsible Party):
Region Skane
ClinicalTrials.gov Identifier:
NCT01699802
First received: September 25, 2012
Last updated: March 4, 2014
Last verified: February 2014
  Purpose

The purpose is to investigate how the adsorptive capacity of the active carbon filter to carbon dioxide in an anaesthetic gas reflector (AnaConDa) is affected by adding inhaled anaesthetic agent.

The hypothesis is that addition of inhaled anaesthetic agent will affect the amount of adsorption of carbon dioxide to the active carbon and thereby affect rebreathing of carbon dioxide.


Condition Intervention
Ischemic Heart Disease
Other: Inhaled anaesthetic agent

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)

Resource links provided by NLM:


Further study details as provided by Region Skane:

Primary Outcome Measures:
  • Volume of carbon dioxide rebreathing from an anesthetic gas reflector [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
    Tidal carbon dioxide volume rebreathed from an anesthetic gas reflector correlated to concentration of delivered anesthetic gas.


Secondary Outcome Measures:
  • Quantification of ventilatory requirements to maintain isocapnia with the use of an anesthetic gas reflector. [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
    Changes of tidal volume required to maintain constant alveolar ventilation will be assessed by continuous measurement of exhaled tidal carbon dioxide volume, the latter to be maintained at a constant value.


Estimated Enrollment: 12
Study Start Date: September 2012
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Inhaled anaesthetic agent
The group where the investigators adds inhaled anaesthetic agent when using the anaesthetic gas reflector (AnaConda).
Other: Inhaled anaesthetic agent

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • elective coronary artery by-pass graft surgery
  • elective valve replacement surgery
  • normal left ventricular ejection fraction on preoperative echocardiography

Exclusion Criteria:

  • obstructive lung disease
  • restrictive lung disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01699802

Contacts
Contact: Gunnar Malmkvist, M.D. Ph.D. +46 46 171035 gunnar.malmkvist@skane.se

Locations
Sweden
Skane University Hospital Lund, Cardiothoracic Intensive Care Recruiting
Lund, Sweden, SE-221 85
Contact: Louise C Walther Sturesson, M.D.    +46 46 171953    louise.walther_sturesson@med.lu.se   
Sponsors and Collaborators
Region Skane
Investigators
Principal Investigator: Mikael Bodelsson, Professor Divison of Surgery, Department of Anaesthesia, Skane University Hospital, Lund, Sweden
  More Information

No publications provided

Responsible Party: Region Skane
ClinicalTrials.gov Identifier: NCT01699802     History of Changes
Other Study ID Numbers: 2012/148
Study First Received: September 25, 2012
Last Updated: March 4, 2014
Health Authority: Sweden: Medical Products Agency

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Heart Diseases
Coronary Disease
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 29, 2014